About UsClinical DevelopmentPartnershipsPatientsInvestorsPress and Media

Recent News

Stay Informed

Click to receive news alerts

Our Mission

  • To advance patient treatment in cancer
  • To apply new insights from molecular and cancer biology to understand how to improve the efficacy and safety of approved and developmental cancer therapies
  • To develop and commercialize a diverse, risk-sensitive portfolio of cancer drugs to address unmet medical needs



May 9, 2008

ZIOPHARM Receives FDA Orphan Drug Designation for Palifosfamide (ZIO-201) in the Treatment of Soft Tissue Sarcoma More

April 17, 2008

ZIOPHARM Announces 2008 Annual Meeting of Stockholders More




Video Media Coverage

Businessweek article
July 23, 2007 issue
More

Businessweek article
May 5, 2008 issue
More

FOX Channel 26 in Houston, recently reported on ZIO-101 Full Coverage

ABC Channel 13 in Houston, Texas, recently reported on ZIO-201 Full Coverage

ABC Channel 13 in Houston, Texas, recently reported on ZIO-101 Full Coverage

ZIO-101 listed as 100 Great Investigational Drugs by R&D Directions More

ZIO-201 listed as 100 Great Investigational Drugs by R&D Directions More

Webcast Events and Presentations

ZIOPHARM 2008 Annual Meeting
April 23, 2008
Click Here for More Information

FORTIS Biotech Conference
April 3, 2008
Click Here for More Information

ROTH 20th Annual OC Growth Stock Conference
February 19, 2008
Click Here for More Information

BMO Capital Markets Focus on Healthcare Conference
December 4, 2007
Click Here for More Information